Chargement en cours...
Combination therapy with copanlisib and ABL tyrosine kinase inhibitors against Philadelphia chromosome-positive resistant cells
ABL tyrosine kinase inhibitor (TKI) therapy has improved the survival of patients with Philadelphia (Ph) chromosome-positive leukemia. However, ABL TKIs cannot eradicate leukemia stem cells. Therefore, new therapeutic approaches for Ph-positive leukemia are needed. Aberrant activation of phosphoinos...
Enregistré dans:
| Publié dans: | Oncotarget |
|---|---|
| Auteurs principaux: | , , , , |
| Format: | Artigo |
| Langue: | Inglês |
| Publié: |
Impact Journals LLC
2016
|
| Sujets: | |
| Accès en ligne: | https://ncbi.nlm.nih.gov/pmc/articles/PMC5288172/ https://ncbi.nlm.nih.gov/pubmed/27437766 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.18632/oncotarget.10605 |
| Tags: |
Ajouter un tag
Pas de tags, Soyez le premier à ajouter un tag!
|